度普利尤单抗治疗3～12岁重度特应性皮炎患儿的临床效果

扫码查看

原文链接

国家科技期刊平台
NETL
NSTL
万方数据

中文摘要：目的:观察度普利尤单抗治疗 3～12 岁中重度特应性皮炎(atopic dermatitis，AD)的效果及安全性。方法:回顾性分析 2022 年 7 月—2023 年 12 月厦门大学附属中山医院诊治的 35 例 3～12 岁中重度AD患儿的临床资料，所有患儿均给予基础治疗与度普利尤单抗治疗，评价并比较治疗前及治疗 4 周、8 周、12 周、16 周患儿湿疹面积及严重程度指数(eczema area and severity index，EASI)、特应性皮炎(scoring atopic dermatitis，SCORAD)评分、研究者整体评估(investigator global assessment，IGA)评分。结果:治疗 4 周，患儿病情严重程度有明显改善，随治疗时间延长，EASI评分、SCORAD评分、IGA评分持续下降，差异有统计学意义(P＜0。001);躯体各部位皮损以躯干改善[90。0%(73。2%，94。5%)]最明显，其次是上肢[85。0%(69。2%，92。3%)]，头颈部[74。0%(58。3%，85。3%)]，下肢[76。0%(61。0%，87。0%)]，总体[80。0%(72。3%，88。3%)]，差异有统计学意义(P＜0。001)。35 例患儿，8 例(22。9%)治疗期间发生不良反应，不良反应均未导致停药。结论:3～12 岁中重度AD患儿采用度普利尤单抗治疗具有良好的效果及安全性，各部位体征躯干皮损改善最明显。

外文标题：Effect of Dupilumab in the Treatment of Moderate to Severe Atopic Dermatitis in Children Aged 3-12 Years

外文摘要：Objective:To observe the effect and safety of Dupilumab in the treatment of moderate to severe atopic dermatitis(AD)in children aged 3-12 years.Method:The clinical data of 35 children with moderate to severe AD aged 3-12 years who diagnosed and treated in Zhongshan Hospital Xiamen University from July 2022 to December 2023 were retrospectively analyzed,all children were treated with basic therapy and Dupilumab,the eczema area and severity index(EASI),scoring atopic dermatitis(SCORAD)score and investigator global assessment(IGA)score were evaluated and compared before treatment and 4 weeks,8 weeks,12 weeks and 16 weeks of treatment.Result:At 4 weeks of treatment,the severity of disease was significantly improved,with the prolongation of treatment time,the EASI score,SCORAD score and IGA score continued to decrease,and the differences were statistically significant(P＜0.001);the most obvious improvement of skin lesions in various parts of body was trunk[90.0%(73.2%,94.5%)],followed by upper limbs[85.0%(69.2%,92.3%)],head and neck[74.0%(58.3%,85.3%)],lower limbs[76.0%(61.0%,87.0%)],and the overall[80.0%(72.3%,88.3%)],the differences were statistically significant(P＜0.001).Among 35 children,8 cases(22.9%)had adverse reactions during treatment,and none of adverse reactions led to drug withdrawal.Conclusion:The treatment of moderate to severe AD in children aged 3-12 years old with Dupilumab has good effect and safety,the improvement of trunk skin lesions in each part was the most obvious..

外文关键词：

Moderate to severeAtopic dermatitisDupilumabEczema area and severity indexAged 3-12 years

作者：

陈美华、沈琼曼、王德辉、谢东斌、郭英俊

展开 >

作者单位：

厦门大学附属中山医院福建厦门 361004

关键词：

中重度特应性皮炎度普利尤单抗湿疹面积及严重程度指数 3～12岁

出版年：

2024

DOI：